---
title: "300199.SZ (300199.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300199.SZ/news.md"
symbol: "300199.SZ"
name: "300199.SZ"
parent: "https://longbridge.com/en/quote/300199.SZ.md"
datetime: "2026-05-20T15:56:09.281Z"
locales:
  - [en](https://longbridge.com/en/quote/300199.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300199.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300199.SZ/news.md)
---

# 300199.SZ (300199.SZ) — Related News

### [HYBIO signed a framework agreement for the sale of peptide raw materials, with a planned sales amount exceeding 327 million yuan](https://longbridge.com/en/news/286908100.md)
*2026-05-19T12:02:05.000Z*
> HYBIO signed a framework agreement for the sale of peptide raw materials, with expected sales exceeding 327 million yuan

### [HYBIO: The Phase III clinical trials for the two domestic indications of Semaglutide injection for weight loss and blood sugar reduction have both achieved equivalence standards](https://longbridge.com/en/news/285364856.md)
*2026-05-06T11:16:03.000Z*
> HYBIO announced that the results of the Phase III clinical trial of its Semaglutide Injection showed that the drug met t

### [The list of growth in contributions from overseas income has been released, with HYBIO, DHI, and others ranking at the forefront](https://longbridge.com/en/news/285031057.md)
*2026-05-04T05:32:37.000Z*
> According to Wind data, there are more than 250 companies whose contribution of overseas revenue is not less than 10% in

### [HYBIO's revenue in 2025 is expected to be 966 million yuan, with accelerated progress in global business layout](https://longbridge.com/en/news/284473111.md)
*2026-04-29T01:29:16.000Z*
> HYBIO (300199) disclosed its 2025 annual report and 2026 first quarter report on April 28. In 2025, the company achieved

### [Torrent obtains exclusive commercialization rights for Lanreotide in the U.S. market from HYBIO](https://longbridge.com/en/news/283454077.md)
*2026-04-21T07:20:55.000Z*
> On April 20th, Shenzhen HYBIO Pharmaceutical Co., Ltd. signed an exclusive development, production, and commercializatio

### [HYBIO signed a product licensing agreement with MCG Pharma to jointly explore the Turkish pharmaceutical market](https://longbridge.com/en/news/282405096.md)
*2026-04-11T05:05:45.000Z*
> HYBIO signed a product licensing agreement with Turkey's MCG Pharma, successfully introducing liraglutide and semaglutid

### [HYBIO: Acetate Glatiramer Injection has received FDA approval in the United States](https://longbridge.com/en/news/275731295.md)
*2026-02-12T09:23:02.000Z*
> HYBIO recently received approval from the U.S. FDA for the Abbreviated New Drug Application (ANDA) certificate for Glati